Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age\> 18 years of age.~* Diagnosis of dyslipidemia.~* That treatment with the fixed-dose combination of rosuvastatin / ezetimibe is documented.~* Have security questioning on at least two occasions.~Exclusion Criteria:~* Subjects who has taken any other statins, fibrates, bile acid sequestrants, niacin (\> 500 mg) or inhibitors of PCSK9 concomitantly during treatment with rosuvastatin / ezetimibe.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A: Rosuvastatin /Ezetimibe fixed dose (TREZETE®) (Type: None): Rosuvastatin /Ezetimibe fixed dose (TREZETE®) Pharmaceutical Form: Tablets Dosage: 10 mg / 10 mg or 20 mg / 10 mg Administration way: Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).